---
figid: PMC9144507__pharmaceuticals-15-00626-g002
figtitle: Metformin and Cancer, an Ambiguanidous Relationship
organisms:
- Nicotiana tabacum
- herbal medicine
- Mycobacterium tuberculosis variant bovis BCG
- Syringa vulgaris
- Mycobacterium tuberculosis variant bovis BCG str. China
- Galega officinalis
- Mycobacterium tuberculosis variant bovis BCG str. Sweden
- Mycobacterium tuberculosis variant bovis BCG str. Mexico
- Homo sapiens
- Rattus norvegicus
- unidentified
- H11N5 subtype
pmcid: PMC9144507
filename: pharmaceuticals-15-00626-g002.jpg
figlink: /pmc/articles/PMC9144507/figure/pharmaceuticals-15-00626-f002/
number: F2
caption: 'Molecular effects of metformin in cancer cells. Metformin directly inhibits
  complex I of the electron transport chain in the mitochondria resulting in decreased
  ATP/AMP ratio and activation of AMPK. AMPK activation inhibits mTOR and activates
  P53 to impact subsequent cellular processes. Metformin also inhibits mTOR in an
  AMPK-independent manner, through Rag GTPases and REDD1. Reduced insulin availability
  through metformin’s systemic effects indirectly modulates the proliferative pathway,
  PI3K/AKT. AMP: Adenosine Monophosphate; AMPK: AMP-Activated Protein Kinase; ATP:
  Adenosine Triphosphate; IGF: Insulin-like Growth Factors; IGF-R: Insulin-like Growth
  Factor Receptor; mTOR: Mammalian Target of Rapamycin; OTC: Organic Cation Transporter;
  PI3K: Phosphoinositide 3-kinase; REDD1: Regulated in Development and DNA damage
  responses 1; SLC: Solute Carrier Transporter; TSC2: Tuberous Sclerosis Complex 2.
  Created in BioRender.'
papertitle: Metformin and Cancer, an Ambiguanidous Relationship.
reftext: Sarah J. Skuli, et al. Pharmaceuticals (Basel). 2022 May;15(5):626.
year: '2022'
doi: 10.3390/ph15050626
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI
keywords: metformin | diabetes | cancer metabolism | AMPK | PI3K | therapeutics |
  drug repurposing
automl_pathway: 0.9670686
figid_alias: PMC9144507__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC9144507__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9144507__pharmaceuticals-15-00626-g002.html
  '@type': Dataset
  description: 'Molecular effects of metformin in cancer cells. Metformin directly
    inhibits complex I of the electron transport chain in the mitochondria resulting
    in decreased ATP/AMP ratio and activation of AMPK. AMPK activation inhibits mTOR
    and activates P53 to impact subsequent cellular processes. Metformin also inhibits
    mTOR in an AMPK-independent manner, through Rag GTPases and REDD1. Reduced insulin
    availability through metformin’s systemic effects indirectly modulates the proliferative
    pathway, PI3K/AKT. AMP: Adenosine Monophosphate; AMPK: AMP-Activated Protein Kinase;
    ATP: Adenosine Triphosphate; IGF: Insulin-like Growth Factors; IGF-R: Insulin-like
    Growth Factor Receptor; mTOR: Mammalian Target of Rapamycin; OTC: Organic Cation
    Transporter; PI3K: Phosphoinositide 3-kinase; REDD1: Regulated in Development
    and DNA damage responses 1; SLC: Solute Carrier Transporter; TSC2: Tuberous Sclerosis
    Complex 2. Created in BioRender.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CCL21
  - PLXNA2
  - APRT
  - MFAP1
  - ATP8A2
  - TP53
  - TP63
  - TP73
  - DDIT4
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - AKT1
  - AKT2
  - AKT3
  - TSC2
  - MTOR
  - IGF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IGF1R
  - Tmprss5
  - Tp53
  - Ccne1
  - Prkaa2
  - Akt1
  - Tsc2
  - Mtor
  - Igf1
  - Pik3cg
  - Igf1r
---
